About Us

History & Milestones

The story of Micro Labs Limited cannot unfold without the story of our founder and inspirational leader, Mr. G C Surana.

He had a humble beginning with a Pharmaceutical Distributor at Bangalore. With valuable years of experience behind him and a dedication towards hard work, Mr. Surana began a marketing and distribution agency for a Delhi-based pharmaceutical company. The agency handled distribution of medicines for the southern states of India.

Micro Labs Private Limited was founded in 1973 at Madras (now known as Chennai). Micro Labs too had a modest beginning with the manufacturing of ethical pharmaceutical preparations. Mr. Surana’s perseverance and leadership was to take Micro Labs from its modest start to its eventual success as a leading name and a shining star in the pharmaceutical industry.

In the decade of the 80’s there was an increased demand for top quality pharmaceutical products. To meet the rising demand, a second manufacturing facility was inaugurated at Hosur, Tamil Nadu, in June 1982. The rising success of Micro Labs encouraged Mr. Surana to begin another pharmaceutical unit – Brown & Burk Pharmaceutical Pvt. Ltd at Complex, Hosur.

As the business grew, in order to meet the ever growing demand in the 90’s, Micro Labs started a new manufacturing Unit – Micro Nova Pharmaceutical Pvt. Ltd., at Peenya Industrial Area, Bangalore. Pondicherry witnessed the setup of a new unit under the flagship of MICRO LABS LIMITED in August 1999.

Over the years, Micro Labs has reinforced its position as an industry leader. The pharmaceutical giant purchased a non-functioning unit in Kumbalgodu Industrial Area on Mysore Road in October 2000, and turned it around. The unit currently manufactures sustained release medicines.

In January 2004, an automated plant specialized to handle only Penicillin based products, began production at Bommasandra Industrial Area. The summer of the same year saw Micro Labs inaugurate a new facility at Goa Industrial Area. It is a formulations plant approved by the US FDA. The plant contains four units that cater exclusively to the export requirements of Micro Labs. Among the units, the first unit started production in November 2004, manufacturing the various Oral Solid dosage forms of Cephalosporin.

Micro Labs was proud to unveil a state-of-the-art ophthalmic plant, the first of its kind in Asia, in July 2006. The plant is designed to manufacture the ophthalmic range of products exclusively. And this exclusivity of the plant has led the company’s strategic collaboration with World’s famous Eye Care company Bausch + Lomb and cater to Asia Pacific markets. This collaboration would also result in joint research and development of Ophthalmic Pharmaceutical Products specifically for emerging markets.

In addition we have a new state of the art facility located at Sikkim.


Today, Micro Labs is a multi-faceted organization with an annual turnover of Rs.4000 crore, including exports that contribute Rs. 1500 crore. The glittering stars of the company are 14 oral formulation plants including an injectable unit; a bulk drug facility, offices located overseas, and a strong distribution network. Our marketing efforts span into 22 divisions, with each division specialized to cater to various therapeutic segments.

The organization’s most important component, however, remains its 12000 dedicated employees.

With state-of-the-art facilities and R&D centres designed to international standards, Micro Labs is poised to become a respected global brand in the pharmaceutical field and highlight our nation’s growing reputation.

The company today, has 20 marketing divisions catering to leading therapeutic segments such as Cardiology, Diabetology, Pain management, Dermatology, Veterinary, Neurology, etc.


  • Report adverse experiences with medications
  • Report serious adverse reactions. A reaction is serious when the patient outcome is:
    • Death
    • Life-threatening (real risk of dying)
    • Hospitalization (initial or prolonged)
    • Disability (significant, persistent or permanent)
    • Congenital anomaly
    • Required intervention to prevent permanent impairment or damage
  • Report even if:
    • You’re not certain the product caused adverse reaction
    • You don’t have all the details however point nos. 1, 5, 7, 8, 11, 15, 16 & 18 (see reverse) are essentially required.
  • Who can report:
    • Any health care professional (Doctors including Dentists, Nurses and Pharmacists).
  • Where to report:
    • After completing, please return this form to Micro Labs Ltd, Pharmacovigilance Cell
  • What happens to the submitted information:
    • Information provided in this form is handled in strict confidence. PV cell at Micro Labs will carry out causality analysis and the data is statistically analysed and finally submitted to CDSCO.


The patient’s identity is held in strict confidence and protected to the fullest extent. Programme staff is not expected to and will not disclose the reporter’s identity in response to a request from the public. Submission of a report does not constitute an admission that medical personnel or manufacturer or the product caused or contributed to the reaction.